{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,7]],"date-time":"2026-06-07T04:29:41Z","timestamp":1780806581619,"version":"3.54.1"},"reference-count":71,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,5]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>\n                      Hepatorenal syndrome (HRS) is a serious complication of decompensated liver cirrhosis that results in acute kidney injury (AKI). The mortality rate is high. Endothelial dysfunction secondary to liver cirrhosis is a key driver of the development of portal hypertension, which is eventually complicated by ascites and HRS. Ultimately, splanchnic vasodilation and excess gut lymph production result in ascites, low effective arterial blood volume, and maladaptive compensatory mechanisms that contribute to renal hypoperfusion and injury. While the only curative treatment is liver transplantation, vasoconstrictors and albumin have been the mainstay of treatment for candidates who are ineligible or waiting for transplantation. On September 14, 2022, terlipressin, a V\n                      <jats:sub>1<\/jats:sub>\n                      vasopressin receptor agonist, was approved by the Food and Drug Administration for the treatment of HRS-AKI. In clinical trials, terlipressin plus albumin have been superior to albumin alone and equivocal to noradrenaline plus albumin in renal function improvement. Terlipressin, however, does not improve survival, is costly, and is associated with severe adverse events\u2014including severe cardiac and vascular complications. The aim of this review is to provide an overview of terlipressin pharmacology, adverse events\u2014with a focus on cardiovascular complications\u2014and comparative randomized controlled trials that resulted in the Food and Drug Administration\u2019s approval of terlipressin. New literature since its approval and ongoing clinical trials will also be highlighted.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/crd.0000000000000697","type":"journal-article","created":{"date-parts":[[2024,6,4]],"date-time":"2024-06-04T12:59:19Z","timestamp":1717505959000},"page":"277-285","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["A Review of Terlipressin in Hepatorenal Syndrome: Targeting Endothelial Dysfunction and Subsequent Cardiovascular Adverse Events"],"prefix":"10.1097","volume":"34","author":[{"given":"Adrienne M.","family":"Bielawski","sequence":"first","affiliation":[{"name":"Department of Medicine, Montefiore Medical Center\/Albert Einstein College of Medicine, Bronx, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William H.","family":"Frishman","sequence":"additional","affiliation":[{"name":"Department of Medicine, New York Medical College, Valhalla, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2024,6,4]]},"reference":[{"key":"R1-20260403","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1002\/hep.31884","article-title":"Diagnosis, evaluation, and management of ascites, spontaneous bacterial peritonitis and hepatorenal syndrome: 2021 practice guidance by the American Association for the Study of Liver Diseases.","volume":"74","author":"Biggins","year":"2021","journal-title":"Hepatology"},{"key":"R2-20260403","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1053\/gast.2000.20189","article-title":"Pentoxifylline improves short-term survival in severe acute alcoholic hepatitis: a double-blind, placebo-controlled trial.","volume":"119","author":"Akriviadis","year":"2020","journal-title":"Gastroenterology"},{"key":"R3-20260403","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/0016-5085(93)90031-7","article-title":"Incidence, predictive factors, and prognosis of the hepatorenal syndrome in cirrhosis with ascites.","volume":"105","author":"Gin\u00e8s","year":"1993","journal-title":"Gastroenterology"},{"key":"R4-20260403","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1002\/hep.1840200619","article-title":"Renal impairment after spontaneous bacterial peritonitis in cirrhosis: incidence, clinical course, predictive factors and prognosis.","volume":"20","author":"Follo","year":"1994","journal-title":"Hepatology"},{"key":"R5-20260403","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S0168-8278(01)68827-5","article-title":"Predictors of morbidity and mortality after the first episode of upper gastrointestinal bleeding in liver cirrhosis.","volume":"32","author":"Del Olmo","year":"2000","journal-title":"J Hepatol"},{"key":"R6-20260403","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1016\/0016-5085(88)90691-9","article-title":"Randomized comparative study of therapeutic paracentesis with and without intravenous albumin in cirrhosis.","volume":"94","author":"Gin\u00e8s","year":"1988","journal-title":"Gastroenterology"},{"key":"R7-20260403","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1016\/j.jhep.2014.12.029","article-title":"Diagnosis and management of acute kidney injury in patients with cirrhosis: revised consensus recommendations of the International Club of Ascites [published correction appears in J Hepatol 2015;63(1):290].","volume":"62","author":"Angeli","year":"2015","journal-title":"J Hepatol"},{"key":"R8-20260403","first-page":"164","article-title":"Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. International Ascites Club.","volume":"23","author":"Arroyo","year":"1996","journal-title":"Hepatology"},{"key":"R9-20260403","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1002\/hep.20687","article-title":"MELD score and clinical type predict prognosis in hepatorenal syndrome: relevance to liver transplantation.","volume":"41","author":"Alessandria","year":"2005","journal-title":"Hepatology"},{"key":"R10-20260403","doi-asserted-by":"crossref","first-page":"4905","DOI":"10.3748\/wjg.v16.i39.4905","article-title":"Alcoholic hepatitis 2010: a clinician\u2019s guide to diagnosis and therapy.","volume":"16","author":"Amini","year":"2010","journal-title":"World J Gastroenterol"},{"key":"R11-20260403","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1002\/hep.24109","article-title":"Tenofovir improves the outcome in patients with spontaneous reactivation of hepatitis B presenting as acute-on-chronic liver failure [published correction appears in Hepatology 2011 Sep 2;54(3):1114].","volume":"53","author":"Garg","year":"2011","journal-title":"Hepatology"},{"key":"R12-20260403","first-page":"406","article-title":"EASL clinical practice guidelines for the management of patients with decompensated cirrhosis [published correction appears in J Hepatol 2018 Nov;69(5):1207].","volume":"69","year":"2018","journal-title":"J Hepatol"},{"key":"R14-20260403","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1016\/S0140-6736(21)01374-X","article-title":"Liver cirrhosis.","volume":"398","author":"Gin\u00e8s","year":"2021","journal-title":"Lancet"},{"key":"R15-20260403","doi-asserted-by":"crossref","first-page":"G473","DOI":"10.1152\/ajpgi.00271.2021","article-title":"Revisiting the gut-liver axis: gut lymphatic system in liver cirrhosis and portal hypertension.","volume":"322","author":"Juneja","year":"2022","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"R16-20260403","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1056\/NEJMra0809139","article-title":"Renal failure in cirrhosis [published correction appears in N Engl J Med 2011 Jan 27;364(4):389].","volume":"361","author":"Gin\u00e8s","year":"2009","journal-title":"N Engl J Med"},{"key":"R17-20260403","doi-asserted-by":"crossref","first-page":"e100009","DOI":"10.1136\/egastro-2023-100009","article-title":"Advances in the diagnosis and management of hepatorenal syndrome: insights into HRS-AKI and liver transplantation.","volume":"1","author":"Arnold","year":"2023","journal-title":"eGastroenterology"},{"key":"R18-20260403","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1016\/j.jhep.2007.02.006","article-title":"Vascular endothelial dysfunction in cirrhosis.","volume":"46","author":"Iwakiri","year":"2007","journal-title":"J Hepatol"},{"key":"R19-20260403","first-page":"34","article-title":"Role of hepatic stellate cells in the pathogenesis of portal hypertension.","volume":"22","author":"Marra","year":"2002","journal-title":"Nefrologia"},{"key":"R20-20260403","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1111\/j.1478-3231.2010.02369.x","article-title":"Angiogenesis in chronic liver disease and its complications.","volume":"31","author":"Coulon","year":"2011","journal-title":"Liver Int"},{"issue":"2 Suppl 1","key":"R21-20260403","doi-asserted-by":"crossref","first-page":"S121","DOI":"10.1002\/hep.20993","article-title":"The hyperdynamic circulation of chronic liver diseases: from the patient to the molecule.","volume":"43","author":"Iwakiri","year":"2006","journal-title":"Hepatology"},{"key":"R22-20260403","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.2215\/CJN.01340406","article-title":"Hepatorenal syndrome: pathophysiology and management.","volume":"1","author":"Wadei","year":"2006","journal-title":"Clin J Am Soc Nephrol"},{"key":"R23-20260403","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1002\/hep.1840080532","article-title":"Peripheral arterial vasodilation hypothesis: a proposal for the initiation of renal sodium and water retention in cirrhosis.","volume":"8","author":"Schrier","year":"1988","journal-title":"Hepatology"},{"key":"R24-20260403","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/0016-5085(86)91124-8","article-title":"Increased synthesis of systemic prostacyclin in cirrhotic patients.","volume":"90","author":"Guarner","year":"1986","journal-title":"Gastroenterology"},{"key":"R26-20260403","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1586\/17474124.1.2.207","article-title":"Pharmacology, clinical efficacy and safety of terlipressin in esophageal varices bleeding, septic shock and hepatorenal syndrome.","volume":"1","author":"Saner","year":"2007","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"R27-20260403","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2147\/JEP.S146034","article-title":"In vitro binding and receptor-mediated activity of terlipressin at vasopressin receptors V1 and V2.","volume":"10","author":"Jamil","year":"2018","journal-title":"J Exp Pharmacol"},{"key":"R28-20260403","first-page":"CD002147","article-title":"Terlipressin for acute esophageal variceal hemorrhage.","volume":"1","author":"Ioannou","year":"2003","journal-title":"Cochrane Database Syst Rev"},{"key":"R29-20260403","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s12871-020-00965-4","article-title":"Terlipressin for the treatment of septic shock in adults: a systematic review and meta-analysis.","volume":"20","author":"Huang","year":"2020","journal-title":"BMC Anesthesiol"},{"key":"R30-20260403","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.cgh.2016.07.016","article-title":"Terlipressin improves renal function and reverses hepatorenal syndrome in patients with systemic inflammatory response syndrome.","volume":"15","author":"Wong","year":"2017","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R31-20260403","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1056\/NEJMoa2008290","article-title":"Terlipressin plus albumin for the treatment of type 1 hepatorenal syndrome.","volume":"384","author":"Wong","year":"2021","journal-title":"N Engl J Med"},{"key":"R32-20260403","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1111\/liv.15367","article-title":"Respiratory events with terlipressin and albumin in hepatorenal syndrome: a review and clinical guidance.","volume":"42","author":"Allegretti","year":"2022","journal-title":"Liver Int"},{"key":"R33-20260403","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1046\/j.1440-1746.2003.02934.x","article-title":"Beneficial effects of terlipressin in hepatorenal syndrome: a prospective, randomized placebo-controlled clinical trial.","volume":"18","author":"Solanki","year":"2003","journal-title":"J Gastroenterol Hepatol"},{"key":"R34-20260403","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.jhep.2007.04.010","article-title":"Noradrenalin vs terlipressin in patients with hepatorenal syndrome: a prospective, randomized, unblinded, pilot study.","volume":"47","author":"Alessandria","year":"2007","journal-title":"J Hepatol"},{"key":"R35-20260403","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1053\/j.gastro.2008.02.014","article-title":"A randomized, prospective, double-blind, placebo-controlled trial of terlipressin for type 1 hepatorenal syndrome.","volume":"134","author":"Sanyal","year":"2008","journal-title":"Gastroenterology"},{"key":"R36-20260403","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1111\/j.1572-0241.2008.01828.x","article-title":"An open label, pilot, randomized controlled trial of noradrenaline versus terlipressin in the treatment of type 1 hepatorenal syndrome and predictors of response.","volume":"103","author":"Sharma","year":"2008","journal-title":"Am J Gastroenterol"},{"key":"R37-20260403","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1053\/j.gastro.2008.02.024","article-title":"Terlipressin and albumin vs albumin in patients with cirrhosis and hepatorenal syndrome: a randomized study.","volume":"134","author":"Mart\u00edn-Llah\u00ed","year":"2008","journal-title":"Gastroenterology"},{"key":"R38-20260403","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1007\/s10620-007-9919-9","article-title":"Terlipressin and albumin in patients with cirrhosis and type I hepatorenal syndrome.","volume":"53","author":"Neri","year":"2008","journal-title":"Dig Dis Sci"},{"key":"R39-20260403","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/j.jhep.2012.01.012","article-title":"Noradrenaline vs. terlipressin in the treatment of hepatorenal syndrome: a randomized study.","volume":"56","author":"Singh","year":"2012","journal-title":"J Hepatol"},{"key":"R40-20260403","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1111\/liv.12179","article-title":"Noradrenaline vs terlipressin in the treatment of type 2 hepatorenal syndrome: a randomized pilot study.","volume":"33","author":"Ghosh","year":"2013","journal-title":"Liver Int"},{"key":"R41-20260403","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1002\/hep.27709","article-title":"Terlipressin plus albumin versus midodrine and octreotide plus albumin in the treatment of hepatorenal syndrome: a randomized trial.","volume":"62","author":"Cavallin","year":"2015","journal-title":"Hepatology"},{"key":"R42-20260403","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1053\/j.gastro.2016.02.026","article-title":"Terlipressin plus albumin is more effective than albumin alone in improving renal function in patients with cirrhosis and hepatorenal syndrome type 1.","volume":"150","author":"Boyer","year":"2016","journal-title":"Gastroenterology"},{"key":"R43-20260403","first-page":"30","article-title":"Noradrenaline is as effective as terlipressin in hepatorenal syndrome type 1: a prospective, randomized trial.","volume":"64","author":"Goyal","year":"2016","journal-title":"J Assoc Physicians India"},{"key":"R44-20260403","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1007\/s12664-018-0876-3","article-title":"Noradrenaline versus terlipressin in the management of type 1 hepatorenal syndrome: a randomized controlled study.","volume":"37","author":"Saif","year":"2018","journal-title":"Indian J Gastroenterol"},{"key":"R45-20260403","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1002\/hep.30208","article-title":"Terlipressin is superior to noradrenaline in the management of acute kidney injury in acute on chronic liver failure.","volume":"71","author":"Arora","year":"2020","journal-title":"Hepatology"},{"key":"R46-20260403","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1007\/s12664-023-01356-6","article-title":"Combination of terlipressin and noradrenaline versus terlipressin in hepatorenal syndrome with early non-response to terlipressin infusion: a randomized trial.","volume":"42","author":"Singh","year":"2023","journal-title":"Indian J Gastroenterol"},{"key":"R47-20260403","first-page":"617","article-title":"Ischemic skin necrosis secondary to the use of terlipressin.","volume":"113","author":"Busta Nistal","year":"2021","journal-title":"Rev Esp Enferm Dig"},{"key":"R48-20260403","first-page":"001247","article-title":"Terlipressin-related ischaemic necrosis of the skin: a rare complication.","volume":"6","author":"Macedo","year":"2019","journal-title":"Eur J Case Rep Intern Med"},{"key":"R49-20260403","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/S1590-8658(03)00225-1","article-title":"Is spontaneous bacterial peritonitis an inducer of vasopressin analogue side-effects? A case report.","volume":"35","author":"Vaccaro","year":"2003","journal-title":"Dig Liver Dis"},{"key":"R50-20260403","first-page":"e36980","article-title":"Terlipressin-induced skin necrosis while managing hepatorenal syndrome: a rare case report from North India.","volume":"15","author":"Sudan","year":"2023","journal-title":"Cureus"},{"key":"R51-20260403","doi-asserted-by":"crossref","first-page":"e233089","DOI":"10.1136\/bcr-2019-233089","article-title":"Terlipressin-induced ischaemic skin necrosis.","volume":"13","author":"Kulkarni","year":"2020","journal-title":"BMJ Case Rep"},{"key":"R52-20260403","doi-asserted-by":"crossref","first-page":"S26","DOI":"10.29271\/jcpsp.2019.06.S26","article-title":"Ischemic skin necrosis in hepatorenal syndrome patient secondary to terlipressin.","volume":"29","author":"Ahmed","year":"2019","journal-title":"J Coll Physicians Surg Pak"},{"key":"R53-20260403","doi-asserted-by":"crossref","first-page":"5","DOI":"10.12659\/AJCR.913150","article-title":"Terlipressin-induced peripheral cyanosis in a patient with liver cirrhosis and hepatorenal syndrome.","volume":"20","author":"Chiang","year":"2019","journal-title":"Am J Case Rep"},{"key":"R54-20260403","doi-asserted-by":"crossref","first-page":"179","DOI":"10.3350\/cmh.2013.19.2.179","article-title":"A case of peripheral gangrene and osteomyelitis secondary to terlipressin therapy in advanced liver disease.","volume":"19","author":"Lee","year":"2013","journal-title":"Clin Mol Hepatol"},{"key":"R55-20260403","first-page":"454","article-title":"A case of peripheral ischemic complication after terlipressin therapy.","volume":"47","author":"Lee","year":"2006","journal-title":"Korean J Gastroenterol"},{"key":"R56-20260403","doi-asserted-by":"crossref","first-page":"434","DOI":"10.2340\/00015555-0651","article-title":"Cutaneous necrosis secondary to terlipressin therapy.","volume":"89","author":"Posada","year":"2009","journal-title":"Acta Derm Venereol"},{"key":"R57-20260403","doi-asserted-by":"crossref","first-page":"788","DOI":"10.4318\/tjg.2012.0490","article-title":"Ischemic skin necrosis following terlipressin therapy: report of two cases and review of the literature.","volume":"23","author":"Ta\u015fliyurt","year":"2012","journal-title":"Turk J Gastroenterol"},{"key":"R58-20260403","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1097\/SGA.0000000000000752","article-title":"Ischemic skin necrosis due to terlipressin use in a patient with hepatorenal syndrome: a case report.","volume":"46","author":"K\u00fc\u00e7\u00fckdemirci","year":"2023","journal-title":"Gastroenterol Nurs"},{"key":"R59-20260403","first-page":"V01180029","article-title":"Severe reversible penile ischaemia after terlipressin treatment of hepatorenal syndrome.","volume":"180","author":"Lange","year":"2018","journal-title":"Ugeskr Laeger"},{"key":"R60-20260403","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.dld.2007.11.009","article-title":"Terlipressin infusion induces ischemia of breast skin in a cirrothic patient with hepatorenal syndrome.","volume":"40","author":"Di Micoli","year":"2008","journal-title":"Dig Liver Dis"},{"key":"R61-20260403","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1097\/MAJ.0b013e3181ee9873","article-title":"Terlipressin-induced skin necrosis and rhabdomyolysis.","volume":"340","author":"Zimmer","year":"2010","journal-title":"Am J Med Sci"},{"key":"R62-20260403","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1016\/j.transproceed.2022.03.023","article-title":"Duodenal necrosis and nonvariceal digestive bleeding after terlipressin administration for treatment of hepatorenal syndrome: a case report of a novel side effect of a commonly used drug.","volume":"54","author":"Cunha","year":"2022","journal-title":"Transplant Proc"},{"key":"R63-20260403","doi-asserted-by":"crossref","first-page":"417","DOI":"10.3350\/cmh.2013.19.4.417","article-title":"Severe ischemic bowel necrosis caused by terlipressin during treatment of hepatorenal syndrome.","volume":"19","author":"Kim","year":"2013","journal-title":"Clin Mol Hepatol"},{"key":"R64-20260403","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1159\/000195676","article-title":"Two observations raising questions about risk factors of cutaneous necrosis induced by terlipressin (Glypressin).","volume":"218","author":"M\u00e9garban\u00e9","year":"2009","journal-title":"Dermatology"},{"key":"R65-20260403","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1007\/s11739-011-0534-6","article-title":"Terlipressin infusion induces Tako-Tsubo syndrome in a cirrhotic man with hepato-renal syndrome.","volume":"6","author":"Di Micoli","year":"2011","journal-title":"Intern Emerg Med"},{"key":"R66-20260403","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1111\/imj.12222","article-title":"Terlipressin-induced QT prolongation.","volume":"43","author":"Sidhu","year":"2013","journal-title":"Intern Med J"},{"key":"R67-20260403","first-page":"505","article-title":"Involvement of the microvasculature in the pathogenesis of terlipressin-related myocardial infarction.","volume":"5","author":"Carmo","year":"2016","journal-title":"Eur Heart J Acute Cardiovasc Care"},{"key":"R68-20260403","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1016\/S1607-551X(09)70266-9","article-title":"Terlipressin-related acute myocardial infarction: a case report and literature review.","volume":"20","author":"Lee","year":"2004","journal-title":"Kaohsiung J Med Sci"},{"key":"R69-20260403","doi-asserted-by":"crossref","first-page":"540.e1","DOI":"10.1016\/j.ajem.2009.08.012","article-title":"Terlipressin-induced severe left and right ventricular dysfunction in patient presented with upper gastrointestinal bleeding: case report and literature review.","volume":"28","author":"Elzouki","year":"2010","journal-title":"Am J Emerg Med"},{"key":"R70-20260403","doi-asserted-by":"crossref","first-page":"257","DOI":"10.4103\/0971-9784.135897","article-title":"Left ventricular failure and left ventricular inferior wall hypokinesia following terlipressin injection.","volume":"17","author":"Ghatak","year":"2014","journal-title":"Ann Card Anaesth"},{"key":"R71-20260403","doi-asserted-by":"crossref","first-page":"5432","DOI":"10.1007\/s12325-023-02674-z","article-title":"Treatment-related cost analysis of terlipressin for adults with hepatorenal syndrome with rapid reduction in kidney function.","volume":"40","author":"Huang","year":"2023","journal-title":"Adv Ther"},{"key":"R72-20260403","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1080\/13696998.2023.2260693","article-title":"Cost-effectiveness of terlipressin for hepatorenal syndrome: the United States hospital perspective.","volume":"26","author":"Carter","year":"2023","journal-title":"J Med Econ"},{"key":"R76-20260403","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1002\/hep.20559","article-title":"The role of transjugular intrahepatic portosystemic shunt in the management of portal hypertension.","volume":"41","author":"Boyer","year":"2005","journal-title":"Hepatology"}],"container-title":["Cardiology in Review"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CRD.0000000000000697","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T14:07:34Z","timestamp":1775225254000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/CRD.0000000000000697"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,4]]},"references-count":71,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/crd.0000000000000697","relation":{},"ISSN":["1538-4683"],"issn-type":[{"value":"1538-4683","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,4]]}}}